Pratley R - Search Results

1

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators. Mosenzon O, et al. Among authors: pratley r. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189517 Free article. Clinical Trial.

2

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE. D'Alessio DA, et al. J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957505 Free PMC article. Clinical Trial.

3

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group. Pratley RE, et al. Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x. Diabetes Obes Metab. 2009. PMID: 19125778 Clinical Trial.

4

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Gilbert MP, Pratley RE. Gilbert MP, et al. Am J Med. 2009 Jun;122(6 Suppl):S11-24. doi: 10.1016/j.amjmed.2009.03.013. Am J Med. 2009. PMID: 19464424 Review.

5

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Gilbert MP, Pratley RE. Gilbert MP, et al. Eur J Intern Med. 2009 Jul;20 Suppl 2:S309-18. doi: 10.1016/j.ejim.2009.05.011. Epub 2009 Jun 21. Eur J Intern Med. 2009. PMID: 19580950 Review.

6

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M. Blonde L, et al. Among authors: pratley re. Diabetes Obes Metab. 2009 Oct;11(10):978-86. doi: 10.1111/j.1463-1326.2009.01080.x. Epub 2009 Jul 13. Diabetes Obes Metab. 2009. PMID: 19614942 Clinical Trial.

7

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. Pratley RE, et al. Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. Lancet. 2010. PMID: 20417856 Clinical Trial.

8

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. DeFronzo RA, et al. Among authors: pratley re. J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14. J Clin Endocrinol Metab. 2012. PMID: 22419732 Clinical Trial.

9

Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.

Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M; 1860-LIRA-DPP-4 Study Group. Pratley RE, et al. Diabetes Care. 2012 Oct;35(10):1986-93. doi: 10.2337/dc11-2113. Epub 2012 Jul 30. Diabetes Care. 2012. PMID: 22851600 Free PMC article. Clinical Trial.

10

Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).

Pratley RE, Urosevic D, Boldrin M, Balena R; T-emerge 6 Study Group. Pratley RE, et al. Diabetes Obes Metab. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30. Diabetes Obes Metab. 2013. PMID: 22958426 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

444 results

Search Page